Following ILMA’s formal request for emergency relief under API 1509, and an exclusive report by F&L Asia that API will announce activation of its Emergency Provisional Licensing (EPL) provisions, attention has turned to how effective the measure will be as Group III base oil disruptions continue.

In essence, API has confirmed a recognized industry disruption and pointed licensees to an existing provision in API 1509—rather than introducing a new broad solution. While EPL offers a pathway for maintaining API licensing, it remains a structured, case-by-case process rather than the blanket waiver some in the industry had hoped for. Its practical impact may therefore be more limited than initial reactions suggest.

Marketers can apply for temporary approval, typically for up to 90 days, to adjust formulations when supply constraints prevent adherence to licensed recipes. However, each applicant must submit supporting data showing that substitute base oils or additives will not compromise performance. This includes evidence of the disruption, efforts to secure alternatives, and technical validation. In some cases, follow-up or retroactive testing may be required, and the exact scope of any additional data API could request remains uncertain.

EPL provides a necessary mechanism, but it does not remove the deeper technical and commercial constraints shaping the market.

For many companies, especially smaller or independent blenders, the time, cost, and technical resources needed may limit how quickly—or whether—they can take advantage of EPL. The framework may function more as a controlled compliance pathway than a rapid operational fix.

More fundamentally, API licensing is not the primary bottleneck. For modern PCMO, especially 0W-20, OEM approvals such as GM’s dexos1 often prove far more restrictive. Even where EPL permits a formulation change, it may still fall outside OEM approval boundaries, limiting commercial viability. In practice, OEM specifications—not API licensing—may ultimately determine how much real flexibility the market has.

The disruption’s impact is uneven. Full synthetic 0W-20 formulations reliant on Group III+ face the greatest pressure. By contrast, 5W-30 PCMO that does not strictly require Group III+ offers considerably more options, especially if GM grants parallel dexos1 relief. Heavy-duty engine oils appear relatively insulated, with any constraints largely limited to certain full synthetic grades where approved base oil supply is more concentrated among a small number of suppliers.

Base oil approvals add further complexity: not all Group III suppliers carry the same OEM approvals, so alternatives may not necessarily be interchangeable.

Taken together, EPL provides a necessary mechanism but does not remove the deeper technical and commercial constraints shaping the market. The situation highlights the interconnected roles of base oil availability, formulation design, and OEM systems in determining how—and how quickly—the industry can respond.

Related articles:

• ILMA Expands Outreach on Group III Supply Concerns, Seeks Relief from GM dexos Program
• ILMA Requests Emergency API Relief as Group III Supply Concerns Grow